Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Restem-L in Polymyositis and Dermatomyositis
NCT04723303Phase 1Completed
- Sponsor
- University of Florida
- Start
- Oct 2021
- Primary completion
- Dec 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Restem-L in polymyositis (PM) and dermatomyositis (DM), sponsored by University of Florida. Primary endpoint: Dose Limiting Toxicity at 24 hours. Started Oct 2021; status: completed.
02
Drugs
Restem-L
03
Conditions
polymyositis (PM)dermatomyositis (DM)
Beyond the preview
Go deeper on NCT04723303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04723303.